Publication|Articles|February 11, 2025
Supplements and Featured Publications
- Role of Spevigo® (spesolimab-sbzo) Injection in the Treatment of Generalized Pustular Psoriasis
Role of Spevigo® (spesolimab-sbzo) Injection in the Treatment of Generalized Pustular Psoriasis
Listen
0:00 / 0:00
This Clinical Brief is supported by Boehringer Ingelheim.
This article provides an overview of generalized pustular psoriasis (GPP) and its clinical and economic impact, and reviews findings of Effisayil® 2, the first trial to study subcutaneous Spevigo® (spesolimab-sbzo) in patients with GPP when not experiencing a flare.
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Latest CME
Trending on AJMC
1
Communication of Launch Prices by Drug Companies, 2022-2024
2
Top 5 Most-Read News Stories of 2025
3
FDA to Accept De-Identified Real-World Evidence for Select Medical Device Applications
4
Bispecifics in New Combos, New Uses, and Earlier Lines of Treatment in Myeloma
5





































